Kevzara (Sarilumab), a New IL-6 Receptor Antagonist Approved for Moderately to Severely Active Rheumatoid Arthritis
Cosentyx (Secukinumab) First IL-17A Antagonist Approved for the Treatment of Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Psoriatic arthritis is an inflammatory form of arthritis that is characterized by swelling, stiffness, and pain and is often accompanied by skin and nail psoriasis; it can affect any joint, including fingers and toes. Psoriatic arthritis affects an estimated 0.3% to 1% of the US population (>3 million people). Furthermore, as many as 30% of individuals with psoriasis will have psoriatic arthritis.
An estimated 7.5 million people in the United States have psoriasis, a chronic, inflammatory, autoimmune disease. Psoriasis is characterized by thick patches of inflamed, scaly skin resulting from excessive proliferation of skin cells. The disease typically affects the scalp, knees, elbows, hands, feet, lower back, and joints; it can also affect nails, the soft tissues of the genitals, and the inside of the mouth. In some cases, psoriasis can lead to disfigurement and disability.
Rasuvo (Methotrexate) Once-Weekly Subcutaneous Injection with Flexible Dosing Approved by the FDA for Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, and Severe Psoriasis
Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis
By Lisa A. Raedler, PhD, RPh, Medical Writer Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease that affects at least 1.3 million adults in the United States.1 Symptoms include pain, stiffness, swelling, and limited motion and function of many joints, particularly the small joints in the hands and feet.1 A diagnosis of RA is made on the basis of symptoms, physical examination results, and blood tests that are positive for anemia, rheumatoid factor, antibodies, and elevated erythrocyte sedimentation rate.1 Continued inflammation of the synovium can lead to cartilage and bone damage.1,2
By Loretta Fala, Medical Writer Psoriatic arthritis (PsA), a chronic, inflammatory disease that causes pain, stiffness, and swelling in and around the joints, generally develops between the ages of 30 and 50 years, but it can affect people of all ages, including children.1 In the United States, the overall prevalence of PsA is estimated to range from 101 to 250 cases per 100,000 people; however, the prevalence of PsA has historically been challenging to determine, because of its misdiagnosis and the lack of widely accepted diagnostic criteria.2 PsA is sometimes misdiagnosed as rheumatoid arthritis, gout, or osteoarthritis.3
Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis
By Lisa A. Raedler, PhD, RPh Systemic juvenile idiopathic arthritis (SJIA) is a rare inflammatory disease, affecting approximately 10% of children diagnosed with juvenile idiopathic arthritis in the United States.1,2 The classic symptoms of SJIA include pain in the small joints of the hands, wrists, knees, and ankles; rash; and a high, spiking fever of ≥103°F that can last for weeks to months.3 By definition, SJIA can present at any point until the age of 16 years. However, a long-term outcomes study found that the median age at diagnosis of SJIA was 4 years.4 The distribution of the disease by sex is roughly equal.
Rituximab the Newest Treatment for Patients with ANCA-Associated Vasculitis, but Cyclophosphamide Still a Viable Option in Severe Disease
Rituximab (Rituxan) is the most recent and the only treatment approved by the US Food and Drug Administration (FDA) for antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but there is still a role for cyclophosphamide in these diseases, especially in patients with more severe forms, according to several researchers. By Wayne Kuznar
Page 1 of 2
Results 1 - 10 of 13
Results 1 - 10 of 13